Tel.: +34 91 736 2385
LOCAL TIME
Contact: Katarina Gluic
Hours: Mon-Thu 8:30-17:00 Fri 8:30-15:00
05:01
For help with a poster, please specify the poster number, the first author and the congress and we will reply shortly.
Poster no.
Contact name
E-mail
Telephone
Congress
Comments

WFH 2014 World Congress

 

11-15 May 2014 Melbourne
FAQs
   
Discussion forum - WFH 2014 World Congress
    Topic - Clinical Issues and Trials

If you are already registered in PosterSessionOnline, enter your e-mail and click on LOGIN. Otherwise click on REGISTER
  
 Thread / Poster  Author  Replies  Last reply
Global Development Plan for a Double Virus Inactivated Fibrinogen Concentrate for the Treatment of Congenital Fibrinogen Deficiency  Anna Klukowska 1      5/5/2014 6:01:00 PM  
Individualized prophylaxis with Human-cl rhFVIII in adult patients with severe haemophilia A  Anna Klukowska 1      5/5/2014 5:58:00 PM  
A Clinical Study In Previously Untreated Patients With Severe Haemophilia A - Immunogenicity, Efficacy and Safety Of Treatment With Human-cl rhFVIII  Anna Klukowska 1      5/5/2014 5:54:00 PM  
Latest Results From The PUP-GCP Clinical Trial: A Low Inhibitor Rate In Previously Untreated Patients With Severe Hemophilia A Treated With Octanate  Anna Klukowska 1      5/5/2014 5:45:00 PM  
EpiNine interim analysis of a non-interventional, multicentre study in patients with haemophilia B  Christoph Koenigs 1      5/2/2014 2:14:00 PM  
Safety and effectiveness of anti inhibitor coagulation complex (AICC) in routine clinical management: a post-authorization safety study (PASS)  Aaron Novack 1      4/23/2014 11:26:00 PM  
Safety Profile of IB1001, Recombinant Factor IX (trenonacog alfa) in the Treatment of Hemophilia B  Hugo Astacio 1      4/23/2014 8:22:00 PM  
Real-life clinical experience of 117 previously untreated patients (PUPs) treated with antihemophilic factor (recombinant), plasma/albumin free method in Japanese post authorization safety surveillance  Masashi Taki 1      4/23/2014 2:41:00 PM  
The Results of Clinical Trial Evaluating of the Efficacy and Safety of Octofactor compared Octanate in the Treatment of Bleeding in Patients with Severe and Moderate Hemophilia A  Nina Klimova 1      4/23/2014 1:03:00 PM  
What we learn from data of a prospective post-authorization safety surveillance study in 384 hemophilia A patients with antihemophilic factor (recombinant) plasma / albumin free method demonstrates safety and efficacy in Japan  KATSUYUKI FUKUTAKE 1      4/23/2014 11:32:00 AM  
PHARMACOKINETIC PROPERTIES, SAFETY AND TOLERABILITY OF NEW B-DOMAIN DELETED RECOMBINANT FACTOR VIII (OCTOFACTOR) IN PATIENTS WITH SEVERE AND MODERATELY SEVERE HEMOPHILIA A  Vladimir Zorenko 1      4/10/2014 2:27:00 PM  
       




Most viewed poster for this congress
Poster: 1
Visits: 2526
Title: A WEB SITE TO IMPROVE MANAGEMENT OF PATIENTS WITH INHERITED BLEEDING DISORDERS IN THE EMERGENCY DEPARTMENT: RESULTS AT 2 YEARS
Authors: Annarita Tagliaferri ,
Centre: Centro di Riferimento Regionale per la cura dellEmofilia

Poster most viewed in this topic
Poster: 43
Visits: 280
Title: A Clinical Study In Previously Untreated Patients With Severe Haemophilia A - Immunogenicity, Efficacy and Safety Of Treatment With Human-cl rhFVIII
Authors: Raina Liesner , M Jansen, S Knaub
Centre: Octapharma Clinical R&D


 








PosterSessionOnline
Logo Draft
 
Logo Cert